S. Koleczko - Univ Hosp Cologne, Cologne, Germany

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 12 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

FP14.04 Resistance to MET Inhibition in MET Driven NSCLC and Response after Switching from Type I to Type II MET Inhibitors

R. Riedel,C. Heydt,A. Scheel, H. Tumbrink,J. Brägelmann,J. Fassunke,L. Nogova,S. Michels,M. Scheffler,R. Fischer,S. Koleczko,J. Weber,

Journal of Thoracic Oncology（2021）

引用3浏览0引用

EATON: A phase I dose-escalation trial of nazartinib (EGF816) and trametinib in EGFR-mutant non-small cell lung cancer (NSCLC) - preliminary data

S. Michels, T. Westphal,L. Nogova,M. Scheffler,B. Deschler-Baier,M. Sebastian,M. Schuler,M. Wermke, D. S. Y. Abdulla, R. N. Fischer,S. Koleczko,A. Kron,

ONCOLOGY RESEARCH AND TREATMENT（2020）

引用0浏览0引用

Small Cell Lung Cancer - Filling the gap between science and patients

J. -P. Weber, R. N. Fischer,J. George, A. Scheel, T. Westphal,S. Koleczko,L. Nogova,R. Riedel,S. Michels,M. Scheffler, D. S. Y. Abdullah, J. Sueptitz,

ONCOLOGY RESEARCH AND TREATMENTno. SUPSUPPL 4 (2020): 154.0-154.0

引用0浏览0引用

KRAS mutations in never-smoker NSCLC patients: Defining a new patient subgroup

M. Scheffler,L. Nogova,S. Michels, A. Holzem, T. Chanra, D. S. Y. Abdulla,S. Koleczko, S. Merkelbach-Bruse, J. Fassunke,A. Kron, A. H. Scheel, M. A. Ihle,

ONCOLOGY RESEARCH AND TREATMENT（2020）

引用0浏览0引用

FIND: a phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC

L. Nogova, F. Malchers,A. M. Hillmer, S. Merkelbach-Bruse,A. Pinto, A. H. Scheel, J. Siemanowski, F. Ueckeroth,M. Scheffler,H. -D. Hummel,J. Kern,M. Wermke,

ONCOLOGY RESEARCH AND TREATMENT（2020）

引用0浏览0引用

Non-small cell lung cancer (NSCLC) patients harboring mutations in FGFR2 and FGFR3: clinical and genomic features

M. Scheffler, T. Chanra,A. Kron,S. Koleczko, D. S. Y. Abdulla, M. A. Ihle,R. Riedel,S. Michels,R. Fischer, S. Merkelbach-Bruse,R. Buettner,L. Nogova,

ONCOLOGY RESEARCH AND TREATMENT（2019）

引用0浏览0引用

OA15.05 BIOLUMA: A Phase II Trial of Nivolumab and Ipilimumab in Lung Cancer – Prospective Evaluation of TMB in SCLC Patients

R. Fischer,J. George,A. Scheel, H. Schlösser, M. Vehreschild,D. Abdulla,S. Koleczko,S. Michels,L. Nogova,R. Riedel,M. Scheffler,L. Maas,

JOURNAL OF THORACIC ONCOLOGY（2019）

引用2浏览0引用

Pharmacokinetics of nintedanib in combination with everolimus in patients with solid tumors - Results from the phase I BARIS trial

M. Scheffler, D. S. Y. Abdulla,S. Koleczko,L. Nogova,S. Michels, R. N. Fischer,R. Riedel, C. Woempner, A. Holzem, M. Thurat,J. Wolf

ONCOLOGY RESEARCH AND TREATMENTno. SUPnan (2018): 309.0-309

引用0浏览0引用

An international platform representing expectations and experiences of young investigators in cancer research - [VI:N]

M. Scheffler,S. Koleczko,C. Teixido,K. El Bairi, D. Morales Espinosa,S. Chatterjee, C. Rolfo, J. Koehler, D. Thommen,S. Ortiz-Cuaran, D. S. Y. Abdulla, V. Brandes,

ONCOLOGY RESEARCH AND TREATMENT（2017）

引用0浏览0引用

Genetic heterogeneity of KRAS-mutated NSCLC leads to different responses to first-line platinum-based chemotherapy

M. Scheffler, D. S. Y. Abdulla,S. Koleczko, M. A. Ihle, S. Merkelbach-Bruse,S. Michels,L. Nogova,A. Kron,R. Fischer, M. Serke,Y. -D. Ko, U. Gerigk,

ONCOLOGY RESEARCH AND TREATMENT（2017）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn